About us

Goals: to improve health outcomes of those with fungal infections or allergies by delivering free educational resources and the latest news to health professionals around the world.

  • Increased awareness of when to suspect a fungal infection in different clinical settings and scenarios
  • Rapid and accurate diagnosis, including selecting the right laboratory tests
  • Selection of the best evidence-based treatment, based on antifungals

Style: clinicians’ time is precious, so we summarise the take-home messages that help you to improve/sharpen your clinical practice. We provide the full text if you want to read the full thing.

Target audience: doctors, nurses, radiologists, laboratory staff, ophthalmologists, critical care units, paediatricians, transplant centres, physiotherapists, epidemiologists, public health professionals, general practitioners, dermatologists, HIV/AIDS centres.

International outlook: each country faces a different set of challenges depending on endemic mycoses and prevalence of underlying factors (e.g. HIV/AIDS, TB). Each healthcare system is different, and may be limited by factors such as funding and which drugs are registered in that country. However, high-quality education in multiple languages can help everyone to make the best of what resources are available.

Location and funding: we are based within the National Aspergillosis Centre at Wythenshawe Hospital (part of Manchester University NHS Foundation Trust). We are supported by the Fungal Infection Trust, a UK charitable foundation set up 20 years ago.

Our team

Professor David Denning has been caring for patients with fungal infections for 30 years.

  • Founded the National Aspergillosis Centre (Manchester, UK), a specialist NHS care commissioning group that treats x00 patients with CPA, ABPA and other forms of aspergillosis and provides information and support to patients and their doctors.
  • Founded the spinout company F2G Ltd, which is currently conducting a phase 2b clinical trial of olorofim (formerly F901318), an orotomide antifungal with a novel mechanism of action.
  • Founded Myconostica Ltd, which develops rapid  molecular diagnostics for invasive fungal infections.
  • Scientific Director of the Fungal Infection Trust, as UK charitable foundation (Charity Commission no. 1147658).
  • President of the Global Action For Fungal Infections (GAFFI), an advocacy organisation that pushes for universal access to fungal diagnostics and treatments, for example by ensuring they are represented on the WHO Essential Diagnostics List and Essential Medicines List.
  • Active participant in drafting guidelines and the mycoses section of the ICD-11.
  • Read his publications

Beth Bradshaw (Medical Writer & Web Manager) joined the LIFE team in 2017.

International advisers

Scroll to top